MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3855/jidc.911

Медицинская библиотека · Journal of infection in developing countries · 2010

Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.

Felga Guilherme, Silva Fernando Marcuz, Barbuti Ricardo Correa, Navarro-Rodriguez Tomas, Zaterka Schlioma, Eisig Jaime Natan

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The scheme proton pump inhibitor/amoxicillin/clarithromycin (PPI/AC) is still the first-line treatment for Helicobacter pylori (H. pylori) infections despite evidence suggesting its failure in up to 20% to 30% of patients.

METHODOLOGY: This study involved 493 patients who were prescribed omeprazole (20 mg twice a day) or another proton pump inhibitor in equivalent dosage, amoxicillin (1 g twice a day), and clarithromycin (500 mg twice a day) for seven days. Efficacy was determined by negative urease test and absence of H. pylori on gastric biopsy samples twelve weeks after the end of treatment. Safety was defined according to the adverse effects reported. Mean age of the patients was (± SD) 48.96 ± 13, and demographic and clinical data were recorded for correlation with treatment outcomes.

RESULTS

Out of 493 patients, 316 (64.1%) presented duodenal ulcer, 111 (22.5%) gastric ulcer, and 66 (14.4%) simultaneous gastric and duodenal ulcers. Additionally, 267 (54.2%) patients had at least one risk factor for peptic ulcer disease, smoking being the most common (99 [36.5%]). Successful eradication was achieved in 408 patients. The eradication rates per protocol, and according to the intention to treat, were 88.8% and 82.7%, respectively.  Of 164 (35.5%) patients who presented adverse effects, 100 (61%) reported them as mild and only six (3.7%) patients had to discontinue treatment. Previous use of tobacco and non-steroid anti-inflammatory drugs was the only risk factor for treatment failure (P = 0.00).

CONCLUSION

PPI/AC is still a valuable and remarkably tolerable option for first-line H. pylori eradication in Brazil.

Для цитирования: Felga Guilherme, Silva Fernando Marcuz, Barbuti Ricardo Correa, Navarro-Rodriguez Tomas, Zaterka Schlioma, Eisig Jaime Natan. Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.. Journal of infection in developing countries. 2010. DOI: 10.3855/jidc.911.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.